Rokx, CasperLammers, JolandaBuitenhuis, LonnekePostma, DouweKoster, DavidLukens, MichaèlScholtens, TheaBoomgaard, Maartje van denKampschreur, LindaUbals Cazorla, MariaPrat, NúriaSoetekouw, RobertVall Mayans, MartíBand, CaterinaCarceles Peiró, VictorGallardo, MireiaCasares Gonzalez, PabloGalvan Femenia, IvanComas Leon, XavierMillat Martínez, PereBassat Orellana, QuiqueGarcia, NadiaGonzález, María IsabelAncochea, ÀguedaGrífols, Joan RamonVerdaguer, JoaquimRoquer López, ClàudiaContreras, EnricGiménez, MontserratArcos Vila, GemmaOuchi, DanBlanco Guillermo, IgnacioVértiz Guidotti, ThatianaBonet Papell, GlòriaDastis Arias, MacarenaDelgado Capel, MariaBriones Zambrano, Ney NicanorFerrer, MagíVidela, SebastiàGudiol González, CarlotaFernández Rivas, GemaCoV-Early Study GroupGarcía, YolandaRuiz Comellas, AnnaVonderen, Marit vanBianco, Andrea SofiaBravo, AnnaOtero, AuremaMillan, AnnaRuibal Suarez, Jose CarlosBenavent, SergioZarauza Pellejero, AlvaroLínio, RosaMalchair, PierreBaro, BàrbaraRoca Font, JuditCarrasco Matos, Katherine M.Saüch Valmaña, GlòriaVidal Obradors, CarlaKatsikis, PeterCapdevila Jáuregui, MarKoopmans, MarionAra, JordiCOnV-ert Study GroupRodríguez Codina, JoanaHernández, LuisTarres García, SilviaBlanco, IgnacioHernández, ÁguedaGonzález Soler, VictoriaCurriu Sabatès, MargaridaFornos, MiriamCasamitjana, NatàliaBordoy, Antoni E.Alonso, EvaGroeneveld, GeertReusken, ChantalZwet, Erik vanMiedema, JelleMüller, YvonneMartinez, NúriaRamírez Morros, AnnaBogers, SusanneMaglio, Laura AnalíaAmado Simon, RosaComellas Fernandez, LauraViozquez Meya, MariaCostes, GèliaPradenas Saavedra, EdwardsForcada, AnnaGammeren, Adriaan vanGinneken, Betty vanHarvala, HeliZwaginga, LisaMarfil, SilviaTroxel, AndreaMooijaart, SimonTrinité, BenjaminSan José, AlbaPiccolo Ferreira, FranciniBonet, MireiaBlanco, JulianCantoni, JordiRusscher, HenkMarks, MichaelOud, JosineZwaginga, Jaap JanTorrano Soler, PamelaMitjà Villar, OriolRijnders, Bart J. A.Droog, José deFerrer, SusanaAlemany Ortiz, AndreaCorbacho Monné, MarcScherpenisse, CeesHollander, Jan denGharbharan, ArvindMeier, RomyRokx, CasperJordans, CarlijnGeurtsvankessel, CorineAlbersen, ArjanPapageourgiou, GrigoriosPuig, JordiEngen, Rene vanKarisli, AytenGötz, HanneloreStruik, JelleDíez Sánchez, BeatrizGonzález Beiras, CamilaParís, AlexaSuñer Navarro, ClaraClotet, Bonaventura, 1953-Reimerink, JohanMaas, NandaRokx-Niemantsverdriet, LotteRodriguez Arias, Miquel AngelJiménez, ZahidaVerstijnen, JoseGeloven, Nan vanSwaneveld, FrancisRamírez Viaplana, FerranSchoot, Ellen van derVrielink, HansLlopis Roca, FerranGonzalez Ruiz, CristianFlores Aguilera, BegoñaVivero Larraza, AinhoaPons Barber, MariaWatering, Leo van deHogema, BorisGonzález García, DavidWijngaarden, Peter vanVidal Alaball, JosepEtten, Ronald vanBerg – Rahman, Juliette van derKarim, FaizHiddema, SiepkeElst, Kim vanNieto Rodríguez, RaquelGarcía García, VanesaCasañ Lopez, CristinaRodriguez Cortez, OrlandoLeeuwen-Segarceanu, Elena vanNieto, AroaRodríguez Sevilla, GracielaReitsma, AnnetteNavarrete Gonzalez, LauraMolenkamp, Karin2022-06-272022-06-272022-05-112041-1723https://hdl.handle.net/2445/187056Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of recruitment target was achieved. A Bayesian-adaptive individual patient data metaanalysis was implemented. Outpatients aged >= 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution.9 p.application/pdfengcc by (c) Rokx, Casper et al, 2022http://creativecommons.org/licenses/by/3.0/es/COVID-19ImmunoregulacióCOVID-19Immunoregulationinfo:eu-repo/semantics/article2022-06-23info:eu-repo/semantics/openAccess35546145